

# Optimizing the MATRix chemotherapy regimen, to reduce side-effects and improve outcomes, for patients with newly diagnosed primary central nervous system lymphoma

<b>Submission date</b> 29/07/2022	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/08/2022	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 17/02/2026	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare disorder that may affect one or several areas of the brain, spinal cord or eye. Current standard of care treatment for newly diagnosed PCNSL patients aged under 70 is 4 cycles of MATRix (induction treatment), which consists of rituximab, cytarabine, methotrexate and thiotepa. This is followed by thiotepa-based high-dose chemotherapy with carmustine or busulfan, then autologous stem cell transplantation (ASCT) (consolidation treatment). The induction treatment is more intensive than some patients can tolerate, resulting in a third of patients unable to have an ASCT, an important part of successful treatment.

This study aims to increase the number of patients that receive ASCT by reducing the toxicity of induction treatment, whilst also improving its effectiveness.

### Who can participate?

Newly diagnosed PCNSL patients will be approached for this study.

### What does the study involve?

Participants will be randomised in a 1:1 ratio between standard of care treatment (control arm) and the experimental arm. The experimental arm consists of one cycle of rituximab and methotrexate, two MATRix drugs that are less toxic. The hypothesis is that this will allow patients to partially recover after their diagnosis so that they are able to better withstand subsequent treatment with MATRix. Patients will then receive abbreviated treatment with 2 cycles of MATRix, then continue to standard of care consolidation treatment. The treatment period is 12 and 16 weeks for the experimental and control arm, respectively. Patients will be followed up to monitor their response to the treatment for a minimum of 2 years after transplant.

There is a translational aspect of the study that aims to analyse tumour biopsy samples and blood to try and identify patients who may be at higher risk of their lymphoma not responding to treatment or returning after treatment has finished.

What are the possible benefits and risks of participating?

Clinical trials are designed to reduce the risks and increase the benefits to the people who take part, regardless of which treatment they get. However, we cannot guarantee any specific treatment benefits or that there are no risks involved when taking part in a clinical trial.

Possible benefits:

- You will be helping to further our knowledge of how to treat PCNSL and this will benefit others with the same condition in the future
- If you have the abbreviated treatment, you may have fewer side effects than you would have if you have the standard care. You may also have a greater chance of undergoing stem cell transplant as consolidation treatment which may increase the chance of successful treatment

Possible risks/disadvantages:

- The trial treatment may not control your PCNSL
- There may be some unpleasant side effects (further information can be found in the Patient Information Sheet)
- There could be risks to your child if you, or your partner, are/or become pregnant, or breastfeeding (further information can be found in the Patient Information Sheet)

Where is the study run from?

Klinikum der Landeshauptstadt Stuttgart gKAöR (Germany)

When is the study starting and how long is it expected to run for?

October 2021 to August 2028

Who is funding the study?

Cancer Research UK

Who is the main contact?

Christopher Wignall, [optimatetrial@soton.ac.uk](mailto:optimatetrial@soton.ac.uk)

Prof Christopher Fox, [christopher.fox@nhs.net](mailto:christopher.fox@nhs.net)

<https://main-site-admin.cms.app.crnnet.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-different-way-of-giving-a-drug-combination-called-matrix-for-people-with>

## Contact information

### Type(s)

Public

### Contact name

Mr Christopher Wignall

### Contact details

Southampton Clinical Trials Unit  
MP131, Southampton General Hospital

Tremona Road  
Southampton  
United Kingdom

SO16 6YD

+44 2381203509

[optimatetrial@soton.ac.uk](mailto:optimatetrial@soton.ac.uk)

**Type(s)**

Principal investigator

**Contact name**

Prof Christopher Fox

**ORCID ID**

<https://orcid.org/0000-0002-6322-9254>

**Contact details**

Nottingham University Hospitals NHS Trust  
Queens Medical Centre  
Derby Road  
Nottingham  
United Kingdom  
NG7 2UH  
+44 1159691169  
christopher.fox@nhs.net

**Additional identifiers****Clinical Trials Information System (CTIS)**

2018-002115

**Integrated Research Application System (IRAS)**

1005070

**ClinicalTrials.gov (NCT)**

NCT04931368

**Protocol serial number**

SCC215/P002900, CPMS 53728

**Study information****Scientific Title**

Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma - a randomized Phase III trial

**Acronym**

OptiMATE

**Study objectives**

A de-escalated induction treatment strategy followed by autologous stem cell transplantation is superior to standard MATRix protocol in terms of event free survival.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 15/09/2022, North West - Greater Manchester South Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK: +44 (0)207 104 8143, gmsouth.rec@hra.nhs.uk), ref: 22/NW/0281

## Study design

Randomized controlled open-label multicenter phase III trial with two parallel arms

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Treatment of primary central nervous system lymphoma (PCNSL) in newly diagnosed patients

## Interventions

Control treatment (Arm A): Patients receive four cycles of MATRix (rituximab 2 x 375 mg/m<sup>2</sup>, HD-MTX 3.5 g/m<sup>2</sup>, HD-AraC 4 x 2 g/m<sup>2</sup>, thiotepa 30 mg/m<sup>2</sup>; i.v.) as induction treatment. Response assessment with gadolinium-enhanced brain MRI (centrally reviewed) takes place after cycles two and four. Patients with at least PR proceed to 3rd cycle of MATRix after first response assessment and to HCT-ASCT (BCNU 400 mg/m<sup>2</sup>, thiotepa 4 x 5 mg/kg; i.v.) after second response assessment. Collection of autologous stem cells is planned after the second cycle of MATRix.

Experimental treatment (Arm B): As induction treatment, patients receive a pre-phase treatment with R/HD-MTX (rituximab 375 mg/m<sup>2</sup>, HD-MTX 3.5g/m<sup>2</sup>; i.v.). In the absence of clinical signs of progression, patients proceed to two cycles of MATRix, followed by a response assessment with gadolinium-enhanced brain MRI (centrally reviewed). Patients achieving at least PR will proceed to HCT-ASCT (BCNU 400 mg/m<sup>2</sup>, thiotepa 4 x 5 mg/kg; i.v.). Collection of autologous stem cells is planned after the first cycle of MATRix.

Duration of treatment per patient:

Control treatment (Arm A): 15 weeks (first cycle until bone marrow recovery after ASCT)

Experimental treatment (Arm B): 11 weeks (first cycle until bone marrow recovery)

Patients will be randomised between treatment arms 1:1. Randomisation will be performed by the local research teams using the Electronic Data Capture system. For OptiMATE, this will be SecuTrial.

## Intervention Type

Drug

## Phase

Phase III

## Drug/device/biological/vaccine name(s)

Rituximab, methotrexate, cytarabine, thiotepa, carmustine/BCNU, busulfan

## Primary outcome(s)

Event-free survival (EFS, defined as time from randomization to premature end of treatment due to any reason, lymphoma progression or death, whichever occurs first) measured using patient records

### **Key secondary outcome(s)**

Measured using patient records unless noted:

1. Overall survival (OS)
2. Progression free survival (PFS)
3. Remission prior to consolidation therapy – RA II
4. Remission after consolidation – 30 days after ASCT
5. Rate of patients reaching consolidation
6. Quality of life (QoL): EORTC QLQ-C30, EORTC QLQ-BN20; measured during screening period, at EOT (30 days after ASCT) and thereafter every 12 months during follow-up.
7. Safety: based on standard criteria for monitoring, assessing and reporting of (serious) adverse events (CTC-AE criteria v5.0), Toxicity will be monitored by taking vital signs and laboratory parameters, Neurotoxicity will be assessed by MoCA/ TMT-A and -B and a neuropsychological test battery, Rate of unplanned hospital admissions, Length of hospital stays (nights in hospital)

### **Completion date**

31/08/2028

## **Eligibility**

### **Key inclusion criteria**

1. Immunocompetent patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system (PCNSL).
2. Male or female patients aged 18-65 years irrespective of ECOG or 66-70 years with ECOG Performance Status  $\leq 2$ .
3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.
4. Disease exclusively located in the CNS.
5. At least one measurable lesion.
6. Previously untreated patients (previous or ongoing steroid treatment admitted).
7. Negative pregnancy test
8. Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease.
9. Ability to understand the nature of the trial and the trial related procedures and to comply with them.

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

65 years

**Sex**

All

**Total final enrolment**

326

**Key exclusion criteria**

1. Congenital or acquired immunodeficiency including HIV infection and previous organ transplantation.
2. Systemic lymphoma manifestation (outside the CNS).
3. Primary vitreoretinal lymphoma or primary leptomeningeal lymphoma without manifestation in the brain parenchyma or spinal cord
4. Previous or concurrent malignancies with the exception of surgically cured carcinoma in situ or other kinds of cancer without evidence of disease for at least 5 years.
5. Previous Non-Hodgkin lymphoma at any time.
6. Inadequate renal function (clearance <60 ml/min).
7. Inadequate bone marrow, cardiac, pulmonary or hepatic function according to investigator's decision
8. Active hepatitis B or C disease.
9. Concurrent treatment with other experimental drugs or participation in an interventional clinical trial with study medication being administered within the last 30 days before the start of this study.
10. Clinically relevant third space fluid accumulation according to the investigator's discretion.
11. Hypersensitivity to study treatment or any component of the formulation.
12. Taking any medications that are likely to cause interactions with the study medication
13. Known or persistent abuse of medication, drugs or alcohol.
14. Active COVID-19-infection or non-compliance with the prevailing hygiene measures regarding the COVID-19 pandemic
15. Patients without legal capacity who are unable to understand the nature, significance and consequences of the trial and without designated legal representative.
16. Previous participation in this trial.
17. Persons who are in a relationship of dependency/ employment with the sponsor and/ or the investigator.
18. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
19. Current or planned pregnancy, nursing period
20. For fertile patients: Failure to use one of the following safe methods of contraception: intra-uterine device or hormonal contraception in combination with a mechanical method of contraception.

**Date of first enrolment**

30/12/2022

**Date of final enrolment**

06/02/2026

# Locations

## Countries of recruitment

United Kingdom

England

Scotland

Wales

Austria

Germany

Italy

## Study participating centre

### **Nottingham University Hospitals NHS Trust - City Campus**

Nottingham City Hospital

Hucknall Road

Nottingham

England

NG5 1PB

## Study participating centre

### **University College London Hospitals NHS Foundation Trust**

250 Euston Road

London

England

NW1 2PG

## Study participating centre

### **University Hospital Southampton NHS Foundation Trust**

Southampton General Hospital

Tremona Road

Southampton

England

SO16 6YD

## Study participating centre

### **Beatson West of Scotland Cancer Centre**

1053 Great Western Road

Glasgow  
Scotland  
G12 0YN

**Study participating centre**

**The Christie NHS Foundation Trust**

550 Wilmslow Road  
Withington  
Manchester  
England  
M20 4BX

**Study participating centre**

**The Newcastle upon Tyne Hospitals NHS Foundation Trust**

Freeman Hospital  
Freeman Road  
High Heaton  
Newcastle upon Tyne  
England  
NE7 7DN

**Study participating centre**

**Leeds Teaching Hospitals NHS Trust**

St. James's University Hospital  
Beckett Street  
Leeds  
England  
LS9 7TF

**Study participating centre**

**Sheffield Teaching Hospitals NHS Foundation Trust**

Northern General Hospital  
Herries Road  
Sheffield  
England  
S5 7AU

**Study participating centre**

**University Hospitals Plymouth NHS Trust**

Derriford Hospital  
Derriford Road

Derriford  
Plymouth  
England  
PL6 8DH

**Study participating centre**  
**Oxford University Hospitals NHS Foundation Trust**  
John Radcliffe Hospital  
Headley Way  
Headington  
Oxford  
England  
OX3 9DU

**Study participating centre**  
**The Clatterbridge Cancer Centre NHS Foundation Trust**  
Clatterbridge Hospital  
Clatterbridge Road  
Bebington  
Wirral  
England  
CH63 4JY

**Study participating centre**  
**University Hospitals of North Midlands NHS Trust**  
Newcastle Road  
Stoke-on-trent  
England  
ST4 6QG

**Study participating centre**  
**King's College Hospital NHS Foundation Trust**  
Department of Haematology  
Denmark Hill  
London  
England  
SE5 9RS

**Study participating centre**  
**Western General Hospital**  
Crewe Road South

Edinburgh  
Lothian  
Scotland  
EH4 2XU

**Study participating centre**  
**University Hospital of Wales**  
Heath Park  
Cardiff  
Wales  
CF14 4XW

**Study participating centre**  
**Hammersmith Hospital**  
Du Cane Road  
Hammersmith  
London  
England  
W12 0HS

**Study participating centre**  
**University Hospitals Birmingham NHS Foundation Trust**  
Queen Elizabeth Hospital  
Mindelsohn Way  
Edgbaston  
Birmingham  
England  
B15 2GW

**Study participating centre**  
**Norfolk and Norwich University Hospitals NHS Foundation Trust**  
Colney Lane  
Colney  
Norwich  
England  
NR4 7UY

## **Sponsor information**

**Organisation**

## Funder(s)

### Funder type

Charity

### Funder Name

Cancer Research UK

### Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

### Funding Body Type

Private sector organisation

### Funding Body Subtype

Other non-profit organizations

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Data sharing statement to be made available at a later date

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes